What is the intention?
$QuantumScape (QS.US)$
On Monday, December 27, US Eastern Time, the QS daily level MACD began to send out technical signals of bottom-up divergence, and QS continued to fall for three consecutive days, forming the K-line combination pattern of the three black crows that underestimated the future market as described in “Sakata Tactics”. Just when people thought it was going to continue to fall, Thursday, December 30 ushered in the rare largest intraday increase of more than 7%, rising 5.08% at the close. Explain that in multi-dimensional causal games, bottom divergence technical factors are stronger than other technical factors.
The increase of +5.08%, especially the biggest increase in the intraday market, once exceeded 7%, causing some people who are good at rising and easily excited to shout, “Continue to empty the rise. Thanks to the bears for their fuel, let's see if they can get past the 40 pressure level.” QS directly opened low and went low on Friday, December 31. Although there was a surge in the intraday period, they all ended in a pullback, and the high point of the range fell every time it surged, almost closing at a single-day low of 22.19 (the day's low was 22.14).
As a result of this decline, in the chip distribution chart, the profit chip ratio was directly reduced to only: 5.47%, far exceeding the standard that profit chips would rebound below 10% to 20%, and it was below 10%. The probability and strength of this rebound will be quite high.
If this is combined with the bottom divergence technical signal sent by the daily level MACD, then the market is likely to rise strongly after New Year's Day.
Conclusion: By establishing a mathematical and physical model of QS to quantitatively analyze the functional curve trajectory equations of stock price fluctuations and technical indicators, combined with traditional technical analysis, there is a high probability that the QS stock price fluctuation trajectory after New Year's Day will move high and go back to the bottom. The limit value of the bottom range is about 19.12, and the median value in the bottom range is 20.32. Currently, none of QS's K-line combinations meet the full requirements of traditional classics. That is, at least one to two Zhongyang lines or Dayang lines with a certain column size. I'm afraid only QuantumScape officially announced the success of its solid-state battery project. However, it must have been too late. Stock prices are skyrocketing. I'm afraid many people can't afford to buy or can only buy a small amount of QS shares. There is no limit on the rise and fall. There is only a fuse mechanism, which mainly prevents a violent rise. There must be quite a few signs before then.
So, the QS daily chart you see so far is at the bottom. A few years later, when the iconic Taiyo line at the bottom was pulled out, what is now called the bottom pattern was instantly reduced to just a few trivial K-line graphics. The K-line chart at the bottom left of the QS daily chart that you see now is like an inconspicuous island at 9.74. On Thursday, September 3, 2020, it simply jumped high at 16.20 and closed at 18.74. Double your rise easily. After that, QS went straight ahead and rocked? The answer is no. On Friday, October 30, 2020, the QS stock price opened high and went low, with a low of 11.25, closing at 11.80, and only one step away from 9.74. I believe many people started to take the road and defraud the gun based on their own customs and inertial thinking. This is to say, there were media reports on 11/12/20. There were media reports on November 12, 2019 Stanley Whittingham, published his views on QuantumScape's solid-state battery project as an independent third party. Highly professional evaluation. As soon as it was reported by the media, Wall Street, which has a keen sense of smell, never lacked capital. The stock price rose almost vertically, reaching a high of 132.73. After that, it began to overdo it and almost fell vertically. Around 40 is almost the bullbear dividing line. This has some extremely important gaps. The lowest point QS has experienced so far is 19.12. A major Wall Street financial institution predicts that the QS fluctuation range is 19.65-32.33, which at least indicates that they also think the 40 area is difficult to overcome in the short term. As for the so-called purchase under 10, there is no technical basis. It is human imagination; it is basically just wishful thinking. Buying at times of bad times, especially when there is a sharp drop, requires wisdom and great courage; it is not something that can be done easily. Human weaknesses are determined by greed and fear and inertial thinking.
If you are interested in going through and carefully studying AMZN's growth history. It was also a loss-making stock at the beginning, but now the historical low price of 1.312 on the daily chart is simply invisible, and you can't find it. On a normal ratio, the lowest price you can see on the daily chart is 1626.03, the lowest price for 52 weeks is 2881, and the lowest price on the weekly chart is 166.97. You can only find 1.312 on the monthly chart. AMZN's closing price on December 31, 2021 was 3334.34, and the closing price for after-hours trading was 3334.88.
Why talk about AMZN? Because AMZN's mathematical model is very similar to the QS model. As to why they are so similar to each other, God knows! I don't know either. As for the starting point, everyone is a loss-making stock or high-tech stock, but the beginning of QS was much higher than AMZN.
Let's also talk about the investment opportunities mentioned in the three cutting-edge technologies that will explode Wall Street in 2022. Among them are the famous QuantumScape and QS, which are hateful and cannot be left out. QS is not showing up here yet.
1. Lithium battery concept: (1) The code is LAC. The current price is 29.12, with a market value of US$3.48 billion. The main business is lithium exploration and production, fair value is 18.38, and the 12-month average target is 35.24 (up 30%). (2) The code is LTHM. The current price is 24.38, and the market value is 4.01 billion US dollars. The main business is lithium composite manufacturing. The fair value is 15.52, and the 12-month average target is 29.77.
2. Psychotropic drug research section: With the development of cannabis in pharmaceuticals over the past few years, some hallucinogens that were once considered illegal drugs have attracted the attention of the medical community. This industry, which is still in its infancy, has received extensive research support in the medical field.
Investors are focusing on this sector for three reasons, including effective treatment for mental health, changing legislative and regulatory improvements, and a broad base of public support. Among them, in the context of the pandemic ravaging the world, this type of medicine has become a tool to treat worsening mental health. British charity Mind said more than two-thirds of young people with mental health issues said their mental health problems worsened significantly during the lockdown. However, we still don't fully understand the impact of the pandemic on human mental health. To address this issue, as long as companies seek to invest heavily in new medical treatments, governments are encouraged to act quickly to protect people's mental health.
In this context, based on research on this type of psychotropic drug, it may be sought after by international capital in 2022. (1). The code is MNMD, and the current price is 1.38. The main business is to develop and develop psychedelic drugs to improve health, promote health and reduce pain. The fair value is 1.51, and the 12-month average target is 8. (2). The code is CYBN, and the current price is 1.20. The main business focuses on developing psychedelic therapy through the use of patented drug discovery platforms, drug delivery systems, new formulation methods, and treatment plans for mental illness. It operates through the following sections: Quiet Living and Nature Trips. The Serene Life Division is engaged in research and development of pharmaceuticals and health products with psilocybin. The Nature Tour section focuses on non-psychedelic medicinal mushroom nutritional food. The fair value is 1.24, and the 12-month average target is 8.20. (3). The code is CMPS. The current price is 22.10. The main business is research and development of psilocybin (Psilocybin) and other psychotherapeutic drugs. Fair value is 17.12, and the 12-month average target is 84.75.
3. Metaverse concept.
Although the concept of “metaverse” is still very controversial, investors have been extremely fond of the concept since Facebook decided to change its name to Meta to focus on the “metaverse.” Some analysts also believe that this will be the next revolution of the internet.
However, since the metaverse is still a vague concept that has yet to be realized, it is not easy for investors to choose good individual stocks. However, in this industry, some companies have lower risk than others.
In fact, many experts believe that instead of betting on companies that want to own companies directly related to the metaverse, it is better to focus on metaverse-based architecture platforms and required technology companies. And in this field, video card and computer chip manufacturers are clearly a good choice.
On the one hand, even without the metaverse, chip stocks are currently in an ideal position, and their artificial intelligence, cloud computing, data centers, etc. could all explode 2022. On the other hand, software stocks can also play a role in the metaverse, and they have graphics technology that are essential to metaverse art and technology creation.
(1). The code is NVDA. The current price is 294.11, the market capitalization is 750.3 billion US dollars. Main business: semiconductor manufacturer, fair value: 222.13, 12-month average target is 360.17.
(2). The code is U, the current price is 142.99, and the market value is 42.24 billion. The main business is software that helps create 3D environments.
Fair value is 98.22, and the 12-month average target is 178.86.
(3). The code is MTTR. The current price is 20.64, and the market value is 5.39 billion. The main business is virtual building replication technology. The fair value is 14.18, the average target for 12 months: 32.33.
Summary review: I have my own stock selection philosophy. 1. I want to choose one that has market demand and a broad future. 2. I don't want so-called blue-chip star stocks that have already risen a lot. In my opinion, the rise is a process of risk accumulation, and the decline is a process of risk release. Even the best stocks go up, and if they rise a lot, they will all fall; it's all a blunder. 3. I don't know why; I just don't like biomedical stocks; the audience is still quite limited. 4. I think it's worth the money. There is a reason why stocks are expensive; there is a reason why cheap is cheap. I don't really like stocks that are too cheap. Single-digit stocks are generally not considered, and the texture is poor.
So I gave up on the psychotropic drug sector.
Let's talk about the metaverse concept section. NVDA is indeed a good stock, but there are many blue-chip star stocks with better performance than it. Second, the stock price has dropped too little, and if the US stock index falls in the future, there won't be much room for it to fall. Wait until the market kills by mistake; even if you kill by mistake, you will have to buy high-performing blue-chip stocks that have also been mistaken but have broader prospects.
The biggest problem with U and MTTR is also that they haven't dropped enough. U closed at 142.99, still a loss-making stock.
In summary, I'm still targeting QS as the target of the transaction, even though this product is always falling and rising less, which is quite annoying. Take your time. The above is just my personal opinion. We don't know each other in the first place. The road is ahead, we all take our own path, do our own thing, and be safe. Happy New Year's Day.
On Monday, December 27, US Eastern Time, the QS daily level MACD began to send out technical signals of bottom-up divergence, and QS continued to fall for three consecutive days, forming the K-line combination pattern of the three black crows that underestimated the future market as described in “Sakata Tactics”. Just when people thought it was going to continue to fall, Thursday, December 30 ushered in the rare largest intraday increase of more than 7%, rising 5.08% at the close. Explain that in multi-dimensional causal games, bottom divergence technical factors are stronger than other technical factors.
The increase of +5.08%, especially the biggest increase in the intraday market, once exceeded 7%, causing some people who are good at rising and easily excited to shout, “Continue to empty the rise. Thanks to the bears for their fuel, let's see if they can get past the 40 pressure level.” QS directly opened low and went low on Friday, December 31. Although there was a surge in the intraday period, they all ended in a pullback, and the high point of the range fell every time it surged, almost closing at a single-day low of 22.19 (the day's low was 22.14).
As a result of this decline, in the chip distribution chart, the profit chip ratio was directly reduced to only: 5.47%, far exceeding the standard that profit chips would rebound below 10% to 20%, and it was below 10%. The probability and strength of this rebound will be quite high.
If this is combined with the bottom divergence technical signal sent by the daily level MACD, then the market is likely to rise strongly after New Year's Day.
Conclusion: By establishing a mathematical and physical model of QS to quantitatively analyze the functional curve trajectory equations of stock price fluctuations and technical indicators, combined with traditional technical analysis, there is a high probability that the QS stock price fluctuation trajectory after New Year's Day will move high and go back to the bottom. The limit value of the bottom range is about 19.12, and the median value in the bottom range is 20.32. Currently, none of QS's K-line combinations meet the full requirements of traditional classics. That is, at least one to two Zhongyang lines or Dayang lines with a certain column size. I'm afraid only QuantumScape officially announced the success of its solid-state battery project. However, it must have been too late. Stock prices are skyrocketing. I'm afraid many people can't afford to buy or can only buy a small amount of QS shares. There is no limit on the rise and fall. There is only a fuse mechanism, which mainly prevents a violent rise. There must be quite a few signs before then.
So, the QS daily chart you see so far is at the bottom. A few years later, when the iconic Taiyo line at the bottom was pulled out, what is now called the bottom pattern was instantly reduced to just a few trivial K-line graphics. The K-line chart at the bottom left of the QS daily chart that you see now is like an inconspicuous island at 9.74. On Thursday, September 3, 2020, it simply jumped high at 16.20 and closed at 18.74. Double your rise easily. After that, QS went straight ahead and rocked? The answer is no. On Friday, October 30, 2020, the QS stock price opened high and went low, with a low of 11.25, closing at 11.80, and only one step away from 9.74. I believe many people started to take the road and defraud the gun based on their own customs and inertial thinking. This is to say, there were media reports on 11/12/20. There were media reports on November 12, 2019 Stanley Whittingham, published his views on QuantumScape's solid-state battery project as an independent third party. Highly professional evaluation. As soon as it was reported by the media, Wall Street, which has a keen sense of smell, never lacked capital. The stock price rose almost vertically, reaching a high of 132.73. After that, it began to overdo it and almost fell vertically. Around 40 is almost the bullbear dividing line. This has some extremely important gaps. The lowest point QS has experienced so far is 19.12. A major Wall Street financial institution predicts that the QS fluctuation range is 19.65-32.33, which at least indicates that they also think the 40 area is difficult to overcome in the short term. As for the so-called purchase under 10, there is no technical basis. It is human imagination; it is basically just wishful thinking. Buying at times of bad times, especially when there is a sharp drop, requires wisdom and great courage; it is not something that can be done easily. Human weaknesses are determined by greed and fear and inertial thinking.
If you are interested in going through and carefully studying AMZN's growth history. It was also a loss-making stock at the beginning, but now the historical low price of 1.312 on the daily chart is simply invisible, and you can't find it. On a normal ratio, the lowest price you can see on the daily chart is 1626.03, the lowest price for 52 weeks is 2881, and the lowest price on the weekly chart is 166.97. You can only find 1.312 on the monthly chart. AMZN's closing price on December 31, 2021 was 3334.34, and the closing price for after-hours trading was 3334.88.
Why talk about AMZN? Because AMZN's mathematical model is very similar to the QS model. As to why they are so similar to each other, God knows! I don't know either. As for the starting point, everyone is a loss-making stock or high-tech stock, but the beginning of QS was much higher than AMZN.
Let's also talk about the investment opportunities mentioned in the three cutting-edge technologies that will explode Wall Street in 2022. Among them are the famous QuantumScape and QS, which are hateful and cannot be left out. QS is not showing up here yet.
1. Lithium battery concept: (1) The code is LAC. The current price is 29.12, with a market value of US$3.48 billion. The main business is lithium exploration and production, fair value is 18.38, and the 12-month average target is 35.24 (up 30%). (2) The code is LTHM. The current price is 24.38, and the market value is 4.01 billion US dollars. The main business is lithium composite manufacturing. The fair value is 15.52, and the 12-month average target is 29.77.
2. Psychotropic drug research section: With the development of cannabis in pharmaceuticals over the past few years, some hallucinogens that were once considered illegal drugs have attracted the attention of the medical community. This industry, which is still in its infancy, has received extensive research support in the medical field.
Investors are focusing on this sector for three reasons, including effective treatment for mental health, changing legislative and regulatory improvements, and a broad base of public support. Among them, in the context of the pandemic ravaging the world, this type of medicine has become a tool to treat worsening mental health. British charity Mind said more than two-thirds of young people with mental health issues said their mental health problems worsened significantly during the lockdown. However, we still don't fully understand the impact of the pandemic on human mental health. To address this issue, as long as companies seek to invest heavily in new medical treatments, governments are encouraged to act quickly to protect people's mental health.
In this context, based on research on this type of psychotropic drug, it may be sought after by international capital in 2022. (1). The code is MNMD, and the current price is 1.38. The main business is to develop and develop psychedelic drugs to improve health, promote health and reduce pain. The fair value is 1.51, and the 12-month average target is 8. (2). The code is CYBN, and the current price is 1.20. The main business focuses on developing psychedelic therapy through the use of patented drug discovery platforms, drug delivery systems, new formulation methods, and treatment plans for mental illness. It operates through the following sections: Quiet Living and Nature Trips. The Serene Life Division is engaged in research and development of pharmaceuticals and health products with psilocybin. The Nature Tour section focuses on non-psychedelic medicinal mushroom nutritional food. The fair value is 1.24, and the 12-month average target is 8.20. (3). The code is CMPS. The current price is 22.10. The main business is research and development of psilocybin (Psilocybin) and other psychotherapeutic drugs. Fair value is 17.12, and the 12-month average target is 84.75.
3. Metaverse concept.
Although the concept of “metaverse” is still very controversial, investors have been extremely fond of the concept since Facebook decided to change its name to Meta to focus on the “metaverse.” Some analysts also believe that this will be the next revolution of the internet.
However, since the metaverse is still a vague concept that has yet to be realized, it is not easy for investors to choose good individual stocks. However, in this industry, some companies have lower risk than others.
In fact, many experts believe that instead of betting on companies that want to own companies directly related to the metaverse, it is better to focus on metaverse-based architecture platforms and required technology companies. And in this field, video card and computer chip manufacturers are clearly a good choice.
On the one hand, even without the metaverse, chip stocks are currently in an ideal position, and their artificial intelligence, cloud computing, data centers, etc. could all explode 2022. On the other hand, software stocks can also play a role in the metaverse, and they have graphics technology that are essential to metaverse art and technology creation.
(1). The code is NVDA. The current price is 294.11, the market capitalization is 750.3 billion US dollars. Main business: semiconductor manufacturer, fair value: 222.13, 12-month average target is 360.17.
(2). The code is U, the current price is 142.99, and the market value is 42.24 billion. The main business is software that helps create 3D environments.
Fair value is 98.22, and the 12-month average target is 178.86.
(3). The code is MTTR. The current price is 20.64, and the market value is 5.39 billion. The main business is virtual building replication technology. The fair value is 14.18, the average target for 12 months: 32.33.
Summary review: I have my own stock selection philosophy. 1. I want to choose one that has market demand and a broad future. 2. I don't want so-called blue-chip star stocks that have already risen a lot. In my opinion, the rise is a process of risk accumulation, and the decline is a process of risk release. Even the best stocks go up, and if they rise a lot, they will all fall; it's all a blunder. 3. I don't know why; I just don't like biomedical stocks; the audience is still quite limited. 4. I think it's worth the money. There is a reason why stocks are expensive; there is a reason why cheap is cheap. I don't really like stocks that are too cheap. Single-digit stocks are generally not considered, and the texture is poor.
So I gave up on the psychotropic drug sector.
Let's talk about the metaverse concept section. NVDA is indeed a good stock, but there are many blue-chip star stocks with better performance than it. Second, the stock price has dropped too little, and if the US stock index falls in the future, there won't be much room for it to fall. Wait until the market kills by mistake; even if you kill by mistake, you will have to buy high-performing blue-chip stocks that have also been mistaken but have broader prospects.
The biggest problem with U and MTTR is also that they haven't dropped enough. U closed at 142.99, still a loss-making stock.
In summary, I'm still targeting QS as the target of the transaction, even though this product is always falling and rising less, which is quite annoying. Take your time. The above is just my personal opinion. We don't know each other in the first place. The road is ahead, we all take our own path, do our own thing, and be safe. Happy New Year's Day.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
70180128 : Long time no see
16718603 OP 70180128 : Hello!
Samur : As I expected, Qs is back below 23 yuan, repeating the history of July. As to whether it can drop to 19 yuan this time, I think it's possible, but it just won't be that fast.